Sun Pharma intros authorized Welchol generic
Sun Pharmaceutical Industries has launched its authorized Welchol generic. The product is indicated as a treatment for hyperlipidemia and to help patients with Type 2 diabetes with glycemic control as an adjunct to diet and exercise.
Sun Pharma’s authorized Welchol generic launch is pursuant to the Mumbai, India-based company’s agreement with Welchol manufacturer Daiichi Sankyo, which grants the company’s U.S. subsidiary exclusive distribution rights for a pre-determined period.
The drug had U.S. sales of roughly $520 million for the 12 months ended March 2018, according to IQVIA data.
Sun Pharma’s authorized Welchol generic launch is pursuant to the Mumbai, India-based company’s agreement with Welchol manufacturer Daiichi Sankyo, which grants the company’s U.S. subsidiary exclusive distribution rights for a pre-determined period.
The drug had U.S. sales of roughly $520 million for the 12 months ended March 2018, according to IQVIA data.